title: [Effect erythropoietin-beta on parameters of erythropoiesis and immunity in patients with diabetes mellitus complicated with diabetic neuropathy and anemia].
abstract: Erythropoiesis indices, number of leucocytes in 1 ml of blood, leukocytic formula, lymphocytes immunophenotype in the patients' blood with diabetes mellitus complicated with diabetic neuropathy and marked normochromal anemia after the treatment with Erythropoietin b have been analyzed in the study. Significant increase in haemoglobin, erythrocytes content, hematocrit indices of peripheral blood has been observed during the treatment. The patients felt better, their quality of life improved, CD3+, CD4+, CD5+ cells and granule-contained lymphocytes content normalized. Serious adverse affects of the medication haven't been observed in the study.
authors.forename: O V
authors.initials: OV
authors.lastname: Ivanchenko
authors.forename: K P
authors.initials: KP
authors.lastname: Zak
authors.forename: M A
authors.initials: MA
authors.lastname: Gruzov
authors.forename: A V
authors.initials: AV
authors.lastname: Kulikovskaia
authors.forename: A S
authors.initials: AS
authors.lastname: Efimov
mesh_terms: D000328:Adult; D000740:Anemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin